1. Search Result
Search Result
Results for "

PCa

" in MedChemExpress (MCE) Product Catalog:

57

Inhibitors & Agonists

1

Screening Libraries

2

Fluorescent Dye

5

Peptides

1

Inhibitory Antibodies

14

Natural
Products

3

Recombinant Proteins

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P10055A

    PSMA-1 TFA

    PSMA Cancer
    PSMA targeting peptide TFA (PSMA-1 TFA) is a PSMA targeting peptide (GRFLTGGTGRLLRIS) and can be used for targeted delivery of glucose-regulated protein (GRP)-silencing siRNAs in PCa cells .
    PSMA targeting peptide TFA
  • HY-101004

    Drug Derivative Others
    PCA 4248 is an active compound.
    PCA 4248
  • HY-U00034

    Drug Derivative Cardiovascular Disease
    PCA50941 is a 1,4-dihydropyridine derivative, used for treatment for cardiovascular disease.
    PCA50941
  • HY-19052

    PCa-4230

    Calcium Channel Cardiovascular Disease
    Trombodipine is an antithrombotic agent, inhibiting platelet aggregation .
    Trombodipine
  • HY-P0021

    Chromozym PCa

    Fluorescent Dye Others
    D-Lys(Z)-Pro-Arg-pNA (Chromozym Pca) is a chromogenic peptide substrate of activated protein C (APC) .
    D-Lys(Z)-Pro-Arg-pNA
  • HY-133587

    Biochemical Assay Reagents Others
    1,1,1,3,10,11-Hexachloroundecane is a kind of polychlorinated alkane (PCA) that has a long carbon chain length .
    1,1,1,3,10,11-Hexachloroundecane
  • HY-N4027

    Hydrangenol 8-O-β-D-glucopyranoside

    Cholinesterase (ChE) Neurological Disease
    Hydrangenol 8-O-glucoside (Hydrangenol 8-O-β-D-glucopyranoside) can be isolated from Hydrangea macrophyllu. Hydrangenol 8-O-glucoside is an AChE inhibitor (IC50: 22.66 μM). Hydrangenol 8-O-glucoside inhibits passive cutaneous anaphylaxis (PCA) reaction .
    Hydrangenol 8-O-glucoside
  • HY-139247

    Drug Derivative Inflammation/Immunology
    pNPS-DHA (Compound 19) is an orally active DHA-ethanolamide (DHEA) derivative that has antiallergic activity. pNPS-DHA inhibits IgE-dependent passive cutaneous anaphylaxis (PCA) reaction in mice. pNPS-DHA has anti-degranulating activity in RBL-2H3 mast cells with an IC50 of 15 μM .
    pNPS-DHA
  • HY-P10816

    Ac-(DLeu)LLLRVK-Amba

    Bacterial Infection Cancer
    PACE4 Inhibitory peptide C23 (Compound C23; Ac-(DLeu)LLLRVK-Amba)), a potent peptidomimetic inhibitor, is a PACE4 inhibitor. PACE4 Inhibitory peptide C23e shows antiproliferative effects against PCa cell lines (Ki = 5 nM; IC50 = 25 and 40 μM for DU145 and LNCaP, respectively). PACE4 Inhibitory peptide C23 also blocks tumor growth in vivo in LNCaP xenograft-bearing mice .
    PACE4 Inhibitory peptide C23
  • HY-173409

    Androgen Receptor Ser/Thr Protease Inflammation/Immunology
    AR antagonist 11 (Compound c2) is a selective AR antagonist with an IC50 of 0.019 μM. AR antagonist 11 is also effective against AR F877L/T878A mutant (IC50: 1.03 μM). AR antagonist 11 inhibits LNCaP cell proliferation and reduces PSA protein expression (IC50: 0.54 μM). AR antagonist 11 can be used for research of prostate cancer (PCa) .
    AR antagonist 11
  • HY-100199

    PSMA Cancer
    HUHS015 is a potent prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitor with an IC50 of 0.67μM for PCA-1 .
    HUHS015
  • HY-120018

    Androgen Receptor Cancer
    VPC-13566, a BF3-specific small molecule, is an androgen receptor (AR) inhibitor. VPC-13566 is effective in inhibiting AR transcriptional activity in vitro as well as the growth of AR-dependent PCa cell lines. VPC-13566 can be used as a chemical probe to help identify unknown AR partners.VPC-13566 can be used for the research of cancer.
    VPC-13566
  • HY-P0021A

    Spectrozyme PCa; Chromozym PCa diacetate

    Fluorescent Dye Others
    D-Lys(Z)-Pro-Arg-pNA diacetate is a chromogenic peptide substrate of activated protein C (APC) .
    D-Lys(Z)-Pro-Arg-pNA diacetate
  • HY-153895

    Estrogen Receptor/ERR Endocrinology
    SLU-PP-1072 is a dual ERRα/γ inverse agonist, used in Prostate cancer (PCa) research. SLU-PP-1072 disrupts PCa cell metabolism, and induces apoptosis via dysregulating cell cycle .
    SLU-PP-1072
  • HY-N7043
    Isosilybin A
    2 Publications Verification

    Apoptosis Cancer
    Isosilybin A, a flavonolignan isolated from silymarin, has anti-prostate cancer (PCA) activity. Isosilybin A inhibits proliferation and induces G1 phase arrest and apoptosis in cancer cells, which activates apoptotic machinery in PCA cells via targeting Akt-NF-κB-androgen receptor (AR) axis .
    Isosilybin A
  • HY-N7043R

    Apoptosis Cancer
    Isosilybin A (Standard) is the analytical standard of Isosilybin A. This product is intended for research and analytical applications. Isosilybin A, a flavonolignan isolated from silymarin, has anti-prostate cancer (PCA) activity. Isosilybin A inhibits proliferation and induces G1 phase arrest and apoptosis in cancer cells, which activates apoptotic machinery in PCA cells via targeting Akt-NF-κB-androgen receptor (AR) axis .
    Isosilybin A (Standard)
  • HY-159926

    RS-7540

    Histamine Receptor Inflammation/Immunology
    Tixanox sodium (RS-7540), an anti-allergic compound, is a potent inhibitor of mediator release in the IgE-mediated passive cutaneous anaphylaxis (PCA) reaction .
    Tixanox sodium
  • HY-106645

    Calmodulin Neurological Disease Inflammation/Immunology
    Cloxacepride is an orally active and potent antiallergic agent. Cloxacepride is a CaM (calmodulin) antagonist. Cloxacepride has anti-PCA (passive cutaneous anaphylaxis) activity .
    Cloxacepride
  • HY-P10055

    PSMA-1

    PSMA Cancer
    PSMA-1 is a PSMA targeting peptide (GRFLTGGTGRLLRIS) and can be used for for targeted delivery of glucose-regulated protein (GRP)-silencing siRNAs in PCa cells. PSMA-1 is selected and polyarginine sequences R6 or R9 were added at the C terminus to generate the CTPs. FITC labeling of the peptide with an aminohexanoic acid (Ahx) linker at the N terminus produced FITC-PSMA-1,to track PSMA binding on PCa cells .
    PSMA targeting peptide
  • HY-163381

    Others Cancer
    Antiproliferative agent-48 (compound PC-A1) shows selective antiproliferative activity against triple-negative breast cancer (TNBC) cells .
    Antiproliferative agent-48
  • HY-N15423

    Others Inflammation/Immunology
    Acrophylline is an antiallergic compound. Acrophylline inhibits mast cell degranulation. Acrophylline reduces the plasma leakage in mouse ear in a passive cutaneous anaphylactic (PCA) reaction. Acrophylline is an alkaloid can be isolated from acronychia haplophylla .
    Acrophylline
  • HY-169349

    Androgen Receptor Cancer
    Androgen receptor antagonist 12 (Compound EF2) is an orally active Androgen receptor (AR) antagonist (IC50: 0.30 μM). Androgen receptor antagonist 12 inhibits transcriptional activity of variant AR mutants and and the proliferation of AR-positive PCa cell lines. Androgen receptor antagonist 12 blocks AR nuclear translocation. Androgen receptor antagonist 12 inhibits tumor growth in a C4-2B xenograft mouse model. Androgen receptor antagonist 12 can be used for prostate cancer (PCa) research .
    Androgen receptor antagonist 12
  • HY-148761

    PSMA I&T; PNT-2002

    PSMA Cancer
    PSMA I&T is an effective inhibitor of prostate-specific membrane antigen (PSMA). PSMA I&T can be used for SPECT/CT imaging and radionuclide studies in triple-negative breast cancer and prostate cancer (PCa) .
    Zadavotide guraxetan
  • HY-W754020

    Histamine Receptor Others
    Elbanizine inhibits histamine, bradykinin, histamin-release from rat mast cells (IC50 of 0.26 μM) and the IgE-mediated passive cutaneous anaphylaxis (PCA) reaction. Elbanizine exhibits antiallergic and antiasthmatic in guinea pig model .
    Elbanizine
  • HY-N12127

    Others Others
    Gymnoside I (compound 1) is a glycosidoxybenzyl 2-isobutylmalic acid. Gymnoside I shows antiallergic activity in passive cutaneous allergic reaction (PCA) in mice. Gymnoside I can be used in research to treat asthma, neurasthenia and chronic hepatitis .
    Gymnoside I
  • HY-162412

    PROTACs Adrenergic Receptor Apoptosis Cancer
    PROTAC AR/AR-V7 degrader-1 (27c) is a PROTAC-based and dual AR, AR-V7 degrader, with DC50 values of 2.67 and 2.64 μM for AR and AR-V7, respectively. PROTAC AR/AR-V7 degrader-1 (27c) induces apoptosis (Red: AR antagonist; Blue: E3 ligase ligand; Black: linker) .
    PROTAC AR/AR-V7 degrader-1
  • HY-172624

    Ligands for Target Protein for PROTAC Cancer
    AR antagonist 14 is is a PROTAC target protein ligand (Ligands for Target Protein for PROTAC). AR antagonist 14 can be combined with VH 101-amide-piperidine-Pip-alkyne (HY-172625) to synthesize PROTAC degraders (ARD-69 (HY-114402)) .
    AR antagonist 14
  • HY-172625

    E3 Ligase Ligand-Linker Conjugates Cancer
    VH 101-amide-piperidine-Pip-alkyne is an E3 Ligase Ligand-Linker Conjugates that can be used to synthesize PROTAC degrader. The linker part of VH 101-amide-piperidine-Pip-alkyne is tert-Butyl 4-ethynyl-[1,4'-bipiperidine]-1'-carboxylate (HY-W442074), and the VHL-type E3 ubiquitinase ligand is VH 101, acid (HY-47070) .
    VH 101-amide-piperidine-Pip-alkyne
  • HY-156751A

    RO7656594

    PROTACs Androgen Receptor Cancer
    GDC-2992 (Compound 28A) is an orally active androgen receptor (AR) degrader. GDC-2992 degrads AR with a DC50 value of 2.7 nM and inhibits proliferation with an IC50 valude of 9.7 nM in VCaPcells. GDC-2992 can be used for prostatic cancer study. (Structure Note: Pink: target protein ligand (HY-130845); Blue: E3 ligase ligand (HY-W1003189A); Black: linker (HY-169975); E3 ligase ligand +linker (HY-169976A)) .
    GDC-2992
  • HY-129503

    Drug Intermediate Others
    2-Heptyl-4-quinolone is an intermediate in the synthesis of the Pseudomonas quinolone signal (PQS) that controls swarming by positively regulating phenazine production. 2-Heptyl-4-quinolone induces the production of the phenazine-1-carboxylic acid (PCA) .
    2-Heptyl-4-quinolone
  • HY-136990

    Others Cancer
    GLPG0259 is a ATP-competitive inhibitor of MAPK-activated protein kinase 5 (MK5) with oral activity. GLPG0259 reduces inflammation and bone destruction in a mouse model of collagen-induced arthritis. GLPG0259 also inhibited the metastasis of prostate cancer (PCa) cells .
    GLPG0259
  • HY-172908

    Androgen Receptor Cancer
    Androgen receptor antagonist 13 (compound 8a) is an orally active Androgen receptor antagonist with an IC50 of 0.20 μM. Androgen receptor antagonist 13 can be used in the study of prostate cancer .
    Androgen receptor antagonist 13
  • HY-137450A

    IMP4297 hydrochloride; JS109 hydrochloride

    PARP Cancer
    Senaparib hydrochloride (IMP4297 hydrochloride) is an oral, selective PARP1/2 inhibitor with potent anti-tumor activity. Senaparib hydrochloride shows antitumor activity against advanced ovarian cancer .
    Senaparib hydrochloride
  • HY-137450

    IMP4297; JS109

    PARP Cancer
    Senaparib (IMP4297) is a highly potent, selective and orally active PARP1/2 inhibitor. Senaparib (IMP4297) exhibits strong antitumor activity in animal models .
    Senaparib
  • HY-N10182

    Histamine Receptor Inflammation/Immunology
    Spinacetin is a natural product that can be isolated from Inula japonica. Spinacetin inhibits the release of histamine. Spinacetin has anti-inflammatory activity .
    Spinacetin
  • HY-159922

    Androgen Receptor Cancer
    AR antagonist 9 is an orally bioavailable selective androgen receptor (AR) antagonist that exerts anticancer effects by disrupting the dimerization of AR ligand-binding domains, showing potential for overcoming drug resistance in prostate cancer (PCa). Its AR antagonistic activity has an IC50 value of 0.051 μM, comparable to Enzalutamide (HY-70002) (IC50 = 0.060 μM). AR antagonist 9 demonstrated superior efficacy against ARF876L/T877A and ARW741C mutants compared to Enzalutamide (HY-70002). Furthermore, AR antagonist 9 exhibited favorable pharmacokinetic properties, with an oral bioavailability of F = 66.24% in rats. In the LNCaP xenograft mouse model, oral administration of AR antagonist 9 significantly inhibited tumor growth. AR antagonist 9 holds promise for research into overcoming PCa drug resistance .
    AR antagonist 9
  • HY-N1434

    Methyl 4-hydroxycinnamate

    Fungal Infection Cancer
    Methyl p-coumarate (Methyl 4-hydroxycinnamate), an orally active esterified derivative of p-Coumaric acid (pCA), can be isolated from the flower of Trixis michuacana var longifolia. Methyl p-coumarate could inhibit the melanin formation in B16 mouse melanoma cells. Methyl p-coumarate also has strong in vitro inhibitory effect on A. alternata and other pathogens .
    Methyl p-coumarate
  • HY-76006

    M-Hydroxybenzaldehyde

    Aldehyde Dehydrogenase (ALDH) NF-κB p38 MAPK Cardiovascular Disease Inflammation/Immunology
    3-Hydroxybenzaldehyde (3-HBA) is a precursor compound for phenolic compounds like Protocatechuic aldehyde (PCA) (HY-N0295). 3-Hydroxybenzaldehyde, produced by 3-hydroxybenzyl-alcohol dehydrogenase, is a substrate of aldehyde dehydrogenase (ALDH) in rats and humans. 3-Hydroxybenzaldehyde has vasculoprotective effects in vitro and in vivo. 3-Hydroxybenzaldehyde is proming for research of atherosclerosis .
    3-Hydroxybenzaldehyde
  • HY-P99274
    Xentuzumab
    1 Publications Verification

    BI 836845; Anti-Human IGF1 and IGF2 Recombinant Antibody

    IGF-1R Cancer
    Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) is a recombinant a human monoclonal antibody that targets IGF ligands IGF1 and IGF2. Xentuzumab inhibits both of IGF1 and IGF2 growth-promoting signalling and suppresses AKT activation .
    Xentuzumab
  • HY-169388

    AUTACs Cancer
    YT 6-2 is the p62/SQSTM1 targeting, autophagy-targeting ligand (ATL) of AUTOTAC ATC-324 (HY-169385), which is an bivalent AR (Androgen Receptor) degrader. ATC-324 can reduce nuclear AR levels and downregulate target gene expression of AR and AR-v7, and also has a degradation effect on common AR mutants in PCa .
    YT 6-2
  • HY-156003

    HDAC Cancer
    HDAC-IN-64 (Compound 13) is a HDAC inhibitor. HDAC-IN-64 inhibits HDAC4/5/6/7/9 with IC50s of 24, 45, 85, 31, 37 nM. HDAC-IN-64 has anti-proliferative activity and anti-migration properties on prostate cancer (PCA) cells. HDAC-IN-64 inhibits LNCaP and RWPE-1 cell growth with GI50 of 0.32 and 1.1 μM respectively .
    HDAC-IN-64
  • HY-129503S

    Isotope-Labeled Compounds Drug Intermediate Others
    2-Heptyl-4-quinolone- 13C6 is the 13C-labeled 2-Heptyl-4-quinolone (HY-129503). 2-Heptyl-4-quinolone is an intermediate in the synthesis of the Pseudomonas quinolone signal (PQS) that controls swarming by positively regulating phenazine production. 2-Heptyl-4-quinolone induces the production of the phenazine-1-carboxylic acid (PCA) .
    2-Heptyl-4-quinolone-13C6
  • HY-129503S1

    Isotope-Labeled Compounds Drug Intermediate Others
    2-Heptyl-4-quinolone- 15N is the 15N-labeled 2-Heptyl-4-quinolone (HY-129503). 2-Heptyl-4-quinolone is an intermediate in the synthesis of the Pseudomonas quinolone signal (PQS) that controls swarming by positively regulating phenazine production. 2-Heptyl-4-quinolone induces the production of the phenazine-1-carboxylic acid (PCA) .
    2-Heptyl-4-quinolone-15N
  • HY-118575

    5-HT Receptor Neurological Disease
    DR-4004 is a 5-HT7 receptor antagonist that attenuates the decreased level of performance produced by mCPP and the performance levels after p-chloroamphetamine (PCA) lesion of the 5-HT system. DR-4004 also reverses amnesia induced by Scopolamine (HY-N0296) and Dizocilpine (HY-15084B). DR-4004 is promising for research of schizophrenia, cognitive deficits and atypical antipsychotic agents .
    DR-4004
  • HY-169386

    AUTACs Cancer
    YT 6-2 analog-1 (compound 2-3) is the p62/SQSTM1 targeting, autophagy-targeting ligand (ATL) of AUTOTAC ATC-324 (HY-169385), which is an bivalent AR (Androgen Receptor) degrader. ATC-324 can reduce nuclear AR levels and downregulate target gene expression of AR and AR-v7, and also has a degradation effect on common AR mutants in PCa .
    YT 6-2 analog-1
  • HY-76006R

    M-Hydroxybenzaldehyde (Standard)

    Aldehyde Dehydrogenase (ALDH) NF-κB p38 MAPK Cardiovascular Disease Inflammation/Immunology
    3-Hydroxybenzaldehyde (Standard) is the analytical standard of 3-Hydroxybenzaldehyde. This product is intended for research and analytical applications. 3-Hydroxybenzaldehyde (3-HBA) is a precursor compound for phenolic compounds like Protocatechuic aldehyde (PCA) (HY-N0295). 3-Hydroxybenzaldehyde, produced by 3-hydroxybenzyl-alcohol dehydrogenase, is a substrate of aldehyde dehydrogenase (ALDH) in rats and humans. 3-Hydroxybenzaldehyde has vasculoprotective effects in vitro and in vivo. 3-Hydroxybenzaldehyde is proming for research of atherosclerosis[1][2][3][4].
    3-Hydroxybenzaldehyde (Standard)
  • HY-169387

    AUTACs Cancer
    YT 6-2-PEG3-C2-NH2 is the p62/SQSTM1 targeting, autophagy-targeting ligand-linker conjugate of AUTOTAC ATC-324 (HY-169385), which is an bivalent AR (Androgen Receptor) degrader. ATC-324 can reduce nuclear AR levels and downregulate target gene expression of AR and AR-v7, and also has a degradation effect on common AR mutants in PCa .
    YT 6-2-PEG3-C2-NH2
  • HY-163438

    Angiotensin-converting Enzyme (ACE) Cardiovascular Disease Cancer
    BKIDC-1553 is an orally active antiglycolytic agent and a bumped kinase inhibitor derived compound with a predicted ~17 h half-life in human. BKIDC-1553 inhibits CYP2C8 and Angiotensin Converting Enzyme and can be used for cancer research .
    BKIDC-1553
  • HY-137557

    APN1607; PM-PBB3

    Biochemical Assay Reagents Neurological Disease
    Florzolotau (APN1607) is a positron emission tomography (PET) ligand that can be used to detect Alzheimer's disease (AD) and other tau proteinopathies. Its binding sites are located in the β-helix of the paired helical filaments (PHFs) and straight filaments (SFs) of the tau protein, as well as in the C-shaped cavity of the SFs. In addition, APN-1607 can bind to the intraneuronal inclusions in Alzheimer's disease (AD), primary age-related tauopathy (PART), and posterior cortical atrophy (PCA). Florzolotau is expected to be used in PET imaging research of neurological diseases, especially tau proteinopathies .
    Florzolotau
  • HY-104040
    MKC8866
    5+ Cited Publications

    Orin1001

    IRE1 Cancer
    MKC8866, a salicylaldehyde analog, is a potent, selective IRE1 RNase inhibitor with an IC50 of 0.29 μM in human vitro. MKC8866 strongly inhibits Dithiothreitol-induced X-box-binding protein 1-spliced (XBP1s) expression with an EC50 of 0.52 μM and unstresses RPMI 8226 cells with an IC50 of 0.14 μM . MKC8866 inhibits IRE1 RNase in breast cancer cells leading to the decreased production of pro-tumorigenic factors and it can inhibits prostate cancer (PCa) tumor growth .
    MKC8866

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: